Evidence map›Paper›PMID 33841132›Full record

ReviewFrontiers in pharmacology2020

Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy.

Verena Hofschröer, Karolina Najder, Micol Rugi, Rayhana Bouazzi, Marco Cozzolino, Annarosa Arcangeli, Gyorgy Panyi, Albrecht Schwab

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Emerging Therapeutic Options in Pancreatic Cancer Management.International journal of molecular sciences · 2024
    Article
  9. Article
  10. Research Progress on TRPA1 in Diseases.The Journal of membrane biology · 2023
    Review
  11. Article
  12. Of Seven New KToxins · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Recombinant Expression inJournal of fungi (Basel, Switzerland) · 2022
    Article
  17. Article
  18. Review
  19. Ion Channel Involvement in Tumor Drug Resistance.Journal of personalized medicine · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Verena HofschröerInstitute of Physiology II, University of Münster, Münster, Germany.
Karolina NajderInstitute of Physiology II, University of Münster, Münster, Germany.
Micol RugiInstitute of Physiology II, University of Münster, Münster, Germany.
Rayhana BouazziDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Marco CozzolinoDepartment of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Annarosa ArcangeliDepartment of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
Gyorgy PanyiDepartment of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Albrecht SchwabInstitute of Physiology II, University of Münster, Münster, Germany.
University of Münster · DEUniversity of Debrecen · HUUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma is a devastating disease with a dismal prognosis. Therapeutic interventions are largely ineffective. A better understanding of the pathophysiology is required. Ion channels contribute substantially to the "hallmarks of cancer." Their expression is dysregulated in cancer, and they are "misused" to drive cancer progression, but the underlying mechanisms are unclear. Ion channels are located in the cell membrane at the interface between the intracellular and extracellular space. They sense and modify the tumor microenvironment which in itself is a driver of PDAC aggressiveness. Ion channels detect, for example, locally altered proton and electrolyte concentrations or mechanical stimuli and transduce signals triggered by these microenvironmental cues through association with intracellular signaling cascades. While these concepts have been firmly established for other cancers, evidence has emerged only recently that ion channels are drivers of PDAC aggressiveness. Particularly, they appear to contribute to two of the characteristic PDAC features: the massive fibrosis of the tumor stroma (desmoplasia) and the efficient immune evasion. Our critical review of the literature clearly shows that there is still a remarkable lack of knowledge with respect to the contribution of ion channels to these two typical PDAC properties. Yet, we can draw parallels from ion channel research in other fibrotic and inflammatory diseases. Evidence is accumulating that pancreatic stellate cells express the same "profibrotic" ion channels. Similarly, it is at least in part known which major ion channels are expressed in those innate and adaptive immune cells that populate the PDAC microenvironment. We explore potential therapeutic avenues derived thereof. Since drugs targeting PDAC-relevant ion channels are already in clinical use, we propose to repurpose those in PDAC. The quest for ion channel targets is both motivated and complicated by the fact that some of the relevant channels, for example, K

Indexed as

fibrosisimmune cellsion channelspancreatic ductal adenocarcinomatherapy

Identifiers

PMID33841132
PMCPMC8025202
OpenAlexW3122443383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.